<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646451</url>
  </required_header>
  <id_info>
    <org_study_id>H-19086</org_study_id>
    <nct_id>NCT00646451</nct_id>
  </id_info>
  <brief_title>Pregabalin in the Treatment of Essential Tremor</brief_title>
  <official_title>A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregabalin is approved for the treatment of nerve pain as well as an additional therapy in&#xD;
      the treatment of seizures. In December 2004, Pfizer gained Food and Drug Administration (FDA)&#xD;
      approval for use of pregabalin in nerve pain associated with diabetes and shingles; making it&#xD;
      the first FDA-approved treatment for both of these nerve pain states.&#xD;
&#xD;
      Tremor is uncontrolled trembling in part of the body. Essential tremor (ET) is associated&#xD;
      with purposeful movement(e.g., holding a glass to drink, shaving, writing and buttoning a&#xD;
      shirt). It occurs most often in the hands and head and also may affect the arms, voice box&#xD;
      (larynx), trunk, and legs. ET is caused by abnormalities in areas of the brain that control&#xD;
      movement. It usually does not result in serious complications.&#xD;
&#xD;
      ET affects approximately 5 million people in the United States. Incidence is highest in&#xD;
      people over the age of 60.&#xD;
&#xD;
      ET usually develops gradually during middle age or later in life. Symptoms may remain mild or&#xD;
      become more severe over time. Stress, fatigue, anxiety, and hot or cold weather can worsen&#xD;
      the disorder. Severe tremor may cause difficulty doing activities of daily living, such as:&#xD;
&#xD;
        -  Brushing hair and teeth&#xD;
&#xD;
        -  Holding a glass without spilling&#xD;
&#xD;
        -  Performing self-care (e.g., getting dressed, shaving, putting on makeup)&#xD;
&#xD;
        -  Using eating utensils&#xD;
&#xD;
        -  Writing and drawing&#xD;
&#xD;
      The purpose of this pilot/feasibility study is to examine the tolerability and efficacy of&#xD;
      Pregabalin in patients with ET.&#xD;
&#xD;
      In other words, can patients diagnosed with ET tolerate high dose of pregabalin? Will the&#xD;
      pregabalin be considered as an efficient medicine in the treatment of ET?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview We propose a single site, double-blind, placebo-controlled, cross-over design. Drug&#xD;
      will be administered in 75mg capsules with a target dose of 300 mg/day. Pregabalin will be&#xD;
      titrated upward as described in the &quot;Summary of Schedule&quot; table with flexibility. During&#xD;
      weeks 3-5 and 12-14, the investigator will have the option of increasing the study drug from&#xD;
      2 capsules per day (150 mg vs. placebo) to 3 or 4 capsules per day if no benefit is noted. If&#xD;
      the dose is increased, it must be done so at a rate of 150mg/day/week. Patients who can not&#xD;
      tolerate a higher dose will be allowed to drop back to a previously tolerated dose but must&#xD;
      be on that dose for one week prior to evaluation. After treatment and clinical assessment,&#xD;
      study drug will be decreased by 150mg/day every 2 days until discontinuation. This pertains&#xD;
      to both the wash out phase and at the end of the study. Both adverse events and need for drug&#xD;
      titration will be conducted during the safety call.&#xD;
&#xD;
      Identical assessments will be done at baseline and at the end of the treatment period for&#xD;
      both drug and placebo. Half of the subjects (group A) will initiate with placebo and then&#xD;
      crossover to drug. The other half (group B) will start treatment with pregabalin and then&#xD;
      crossover to placebo.&#xD;
&#xD;
      The primary endpoint will be the change in Fahn-Tolosa-Marin Tremor Rating Scale (TRS) from&#xD;
      baseline. Scale has Parts A= (severity of rest, action &amp; postural tremor in upper and lower&#xD;
      extremities, face, voice, tongue, head &amp; trunk), B= (severity of tremor writing, drawing &amp;&#xD;
      pouring), C= (functional disability while speaking, eating, drinking, maintaining hygiene,&#xD;
      dressing &amp; working) and the total summed.&#xD;
&#xD;
      Other clinical assessments will include Clinical Global Impression of Change (CGI-C), Quality&#xD;
      of Life in Essential Tremor Questionnaire (QUEST) maximum score =100, Hamilton Anxiety Scale&#xD;
      (HAM-A) score 0-17 = mild, 18-24 = moderate, and 25-30 moderate to severe, and a sleep&#xD;
      hygiene questionnaire rating across 5 domains- physical symptoms, energy &amp; motivation,&#xD;
      concentration, interpersonal relations, and psychological symptoms (HD-16). For the TRS,&#xD;
      HAM-A, QUEST, and HD-16 higher scores represent increased symptom severity or diminished&#xD;
      quality of life and the CGI-C is scored as follows: 1=very much improved, 2=much improved, 3=&#xD;
      mildly improved, 4=no change, 5= mildly worse, 6= much worse, and 7=very much worse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tremor Rating Scale (TRS) Compared With Baseline.</measure>
    <time_frame>baseline to 6 weeks</time_frame>
    <description>Change from baseline in the overall TRS score obtained at the final evaluation (end of study). The overall TRS score will be derived from the three TRS subscales. The minimum and maximum score for part A is 0-80, part B is 0-36, and part C is 0-28 giving a maximum score of 144. TRS part A rates the severity of resting, postural and action tremor in upper and lower extremities, face, tongue, voice, head and trunk. Part B rates the severity of upper extremity tremor while writing, drawing, and pouring liquid. Part C rates functional disability of tremor while speaking, eating, drinking, maintaining hygiene, dressing, and working. Higher scores represent increased symptom severity or diminished quality of life.&#xD;
.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures Quality of Life in Essential Tremor (QUEST), Hamilton Anxiety Scale (HAM-A), Hotel Dieu-16 a Sleep Hygiene Questionnaire(HD-16), and Clinical Clobal Impression-Change Scale (CGI-C)</measure>
    <time_frame>baseline to 6 weeks</time_frame>
    <description>The Quality of Life in Essential Tremor Questionnaire (QUEST), Hamilton Anxiety scale (HAM-A) and Hotel Dieu-16 (HD-16) were scored as per published guidelines [7], [8] and [9]. The QUEST rates patient perception as influenced by tremor across 5 domains. A QUEST score will be between 0 and 120 with 0 = no essential tremor and 120 = severe essential tremor. The HAM-A rates the severity of anxiety symptomatology across 14 parameters. Scores of 14-17 = mild anxiety, 18-24 = moderate anxiety, and 25-30 = severe anxiety; The HD-16 rates insomnia-related quality of life across five domains. An HD-16 score of 73.1 - 248.5 = severe insomnia, 61-73.1 = mild insomnia, and 0 - 61 = good sleeper. For the scales, HAM-A, QUEST and HD-16, higher scores represent increased symptom severity or diminished quality of life. CGI-C was scored as follows: 1 = very much improved, 2=much improved, 3=mildly improved, 4=no change, 5=mildly worse, 6= much worse, and 7= very much worse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Pregabalin (Lyrica)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin (Lyrica) 75 mg bid to a maximum dose of 300 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to 4 capsules bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin (Lyrica)</intervention_name>
    <description>75 mg bid to 300 mg bid based on per subject tolerability</description>
    <arm_group_label>Pregabalin (Lyrica)</arm_group_label>
    <other_name>pregabalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>up to 4 capsules bid as tolerated</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be between the ages of 18 and 80 inclusive.&#xD;
&#xD;
          2. Each subject must have current manifestations of ET symptoms based on the Tremor&#xD;
             Investigational Group (TRIG) criteria for definite or probable ET: - Moderate or&#xD;
             severe tremor in head or arms for at least 3 years duration. - No present causes of&#xD;
             enhanced physiologic tremor. - No recent exposure to tremorogenic drugs or drug&#xD;
             withdrawal states. - No direct or indirect trauma to the nervous system within 3&#xD;
             months preceding the onset of tremor. - No historic or clinical evidence of&#xD;
             psychogenic tremor origin.&#xD;
&#xD;
          3. Subjects with a history of seizures are eligible.&#xD;
&#xD;
          4. Subjects must be in generally good health as evidenced by previous medical history and&#xD;
             clinical examination.&#xD;
&#xD;
          5. Patients will be allowed to take Beta-blockers but will not be allowed to take any&#xD;
             other medication for tremor (primidone, topiramate, benzodiazepines, etc.) An evening&#xD;
             dose of a benzodiazepine to improve sleep is acceptable. They must have been on a&#xD;
             stable dose of any existing beta-blocker for 4 weeks prior to entry into the study and&#xD;
             will not be allowed to change the dose of that medication throughout the controlled&#xD;
             portion of the study. Any medication discontinued during screening in order to comply&#xD;
             with these criteria must be stopped for 5 half-lives prior to study initiation.&#xD;
&#xD;
          6. Subjects must be accessible by telephone.&#xD;
&#xD;
          7. If the subject is a female of childbearing age, she must have had a hysterectomy,&#xD;
             tubal ligation, otherwise be incapable of pregnancy, or have practiced one of the&#xD;
             following methods of contraception for at least one month prior to study entry (or a&#xD;
             negative urine pregnancy test within one week of study entry): - Hormonal&#xD;
             contraceptives - Spermicide and barrier - Intrauterine device - Partner sterility&#xD;
&#xD;
          8. Prior to participation in this study, each subject must sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients do not meet TRIG criteria for probable ET.&#xD;
&#xD;
          2. Subjects who are not able to abstain from alcohol for 24 hours prior to each&#xD;
             evaluation.&#xD;
&#xD;
          3. Patients who can not maintain an identical dose of any medicine that may affect tremor&#xD;
             during their entire study involvement.&#xD;
&#xD;
          4. Subjects who have exhibited any psychotic symptomatology.&#xD;
&#xD;
          5. Subjects who have known renal deficiencies.&#xD;
&#xD;
          6. Subjects who have been intolerant of pregabalin in the past&#xD;
&#xD;
          7. Prior surgical treatment for tremor.&#xD;
&#xD;
          8. Patients currently taking more than a single drug for ET.&#xD;
&#xD;
          9. Patients taking anti-seizure medications.&#xD;
&#xD;
         10. Breast feeding or pregnant females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Jankovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PDCMDC 6550 Fannin, Suite 1801</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009 Oct 15;285(1-2):195-7. doi: 10.1016/j.jns.2009.06.044. Epub 2009 Jul 25.</citation>
    <PMID>19631949</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <results_first_submitted>February 17, 2016</results_first_submitted>
  <results_first_submitted_qc>March 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2021</results_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Joseph Jankovic</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Essential tremor</keyword>
  <keyword>Activities of Daily Living (ADL's)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin First, Then Placebo</title>
          <description>Pregabalin: 75 mg bid to 300 mg bid based on per subject tolerability. Study crossover design. Patients were randomized for treatment with PGB or placebo, titrated over 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Pregabalin</title>
          <description>Placebo capsules: up to 4 capsules bid as tolerated. Study crossover design. Patients were randomized for treatment with PGB or placebo, titrated over 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exacerbation of pre-existing condition</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study crossover design. Patients were randomized for treatment with PGB or placebo, titrated over 6 weeks. TRS (primary endpoint), then CGI-C, QUEST, HAM-A, and HD-16 secondary endpoints at end of treatment periods for both drug and placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Demographics and clinical characteristics of participants at study initiation are listed in Table 1 of the paper. Sixteen of 20 patients completed the study and were included in the analysis of drug efficacy (Table 2).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tremor Rating Scale (TRS)</title>
          <description>a TRS part A rates the severity of resting, postural and action tremor in upper and lower extremities, face, tongue, voice, head and trunk. Part B rates the severity of upper extremity tremor while writing, drawing, and pouring liquid. Part C rates functional disability of tremor while speaking, eating, drinking, maintaining hygiene, dressing, and working. (0: no tremor, 1: barely perceptible tremor, 2: &lt; 2 cm, 3: 2-4 cm, and 4: &gt; 4 cm). The higher scores represent increased symptom severity or diminished QoL.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>TRS Part A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRS Part B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRS Part C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRS total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Tremor Rating Scale (TRS) Compared With Baseline.</title>
        <description>Change from baseline in the overall TRS score obtained at the final evaluation (end of study). The overall TRS score will be derived from the three TRS subscales. The minimum and maximum score for part A is 0-80, part B is 0-36, and part C is 0-28 giving a maximum score of 144. TRS part A rates the severity of resting, postural and action tremor in upper and lower extremities, face, tongue, voice, head and trunk. Part B rates the severity of upper extremity tremor while writing, drawing, and pouring liquid. Part C rates functional disability of tremor while speaking, eating, drinking, maintaining hygiene, dressing, and working. Higher scores represent increased symptom severity or diminished quality of life.&#xD;
.</description>
        <time_frame>baseline to 6 weeks</time_frame>
        <population>Indistinguishable capsules and an identical titration protocol were used for PGB and placebo. Patients received the study drug at an initial dose of 75 mg twice daily, with upward titration to a target dose of 150 mg bid up to 300 mg bid. The study drug was increased at a rate of 150 mg/day/week.</population>
        <group_list>
          <group group_id="O1">
            <title>1-Pregabalin</title>
            <description>pregabalin : 75 mg bid to 300 mg bid based on per subject tolerability. Crossover study design and measure change in TRS Pregabalin group versus placebo group.</description>
          </group>
          <group group_id="O2">
            <title>2-Placebo</title>
            <description>placebo capsules : up to 4 capsules bid as tolerated. Crossover study design and measure change in TRS Pregabalin group versus placebo group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tremor Rating Scale (TRS) Compared With Baseline.</title>
          <description>Change from baseline in the overall TRS score obtained at the final evaluation (end of study). The overall TRS score will be derived from the three TRS subscales. The minimum and maximum score for part A is 0-80, part B is 0-36, and part C is 0-28 giving a maximum score of 144. TRS part A rates the severity of resting, postural and action tremor in upper and lower extremities, face, tongue, voice, head and trunk. Part B rates the severity of upper extremity tremor while writing, drawing, and pouring liquid. Part C rates functional disability of tremor while speaking, eating, drinking, maintaining hygiene, dressing, and working. Higher scores represent increased symptom severity or diminished quality of life.&#xD;
.</description>
          <population>Indistinguishable capsules and an identical titration protocol were used for PGB and placebo. Patients received the study drug at an initial dose of 75 mg twice daily, with upward titration to a target dose of 150 mg bid up to 300 mg bid. The study drug was increased at a rate of 150 mg/day/week.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TRS Part A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="4.7"/>
                    <measurement group_id="O2" value="-0.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRS Part B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="12.3"/>
                    <measurement group_id="O2" value="3.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRS Part C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="13.9"/>
                    <measurement group_id="O2" value="-1.5" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total TRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="9.7"/>
                    <measurement group_id="O2" value="0.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome Measures Quality of Life in Essential Tremor (QUEST), Hamilton Anxiety Scale (HAM-A), Hotel Dieu-16 a Sleep Hygiene Questionnaire(HD-16), and Clinical Clobal Impression-Change Scale (CGI-C)</title>
        <description>The Quality of Life in Essential Tremor Questionnaire (QUEST), Hamilton Anxiety scale (HAM-A) and Hotel Dieu-16 (HD-16) were scored as per published guidelines [7], [8] and [9]. The QUEST rates patient perception as influenced by tremor across 5 domains. A QUEST score will be between 0 and 120 with 0 = no essential tremor and 120 = severe essential tremor. The HAM-A rates the severity of anxiety symptomatology across 14 parameters. Scores of 14-17 = mild anxiety, 18-24 = moderate anxiety, and 25-30 = severe anxiety; The HD-16 rates insomnia-related quality of life across five domains. An HD-16 score of 73.1 - 248.5 = severe insomnia, 61-73.1 = mild insomnia, and 0 - 61 = good sleeper. For the scales, HAM-A, QUEST and HD-16, higher scores represent increased symptom severity or diminished quality of life. CGI-C was scored as follows: 1 = very much improved, 2=much improved, 3=mildly improved, 4=no change, 5=mildly worse, 6= much worse, and 7= very much worse.</description>
        <time_frame>baseline to 6 weeks</time_frame>
        <population>Change in secondary measures of efficacy compared with baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Patients received the study drug at an initial dose of 75 mg twice daily, with upward titration to a target dose of 150 mg twice daily. Patients were given the option to increase the study drug to as high as 300 mg twice daily if inadequate benefit was perceived after 3 weeks of treatment. The study drug was increased at a rate of 150 mg/day/week. All patients in both periods were contacted by phone after two weeks of treatment to facilitate drug titration and address any adverse events. Patients were permitted to return to a lower dose if side effects occurred during drug titration.&#xD;
After assessment protocols were completed, patients were titrated off the study drug at a rate of 150 mg every 2 days until discontinuation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients received the study drug/matching placebo at an initial dose of 75 mg twice daily, with upward titration to a target dose of 150 mg twice daily. Patients were given the option to increase the study drug to as high as 300 mg twice daily if inadequate benefit was perceived after 3 weeks of treatment. The study drug was increased at a rate of 150 mg/day/week. All patients in both periods were contacted by phone after two weeks of treatment to facilitate drug titration and address any adverse events. Patients were permitted to return to a lower dose if side effects occurred during drug titration.&#xD;
After assessment protocols were completed, patients were titrated off the study drug at a rate of 150 mg every 2 days until discontinuation.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome Measures Quality of Life in Essential Tremor (QUEST), Hamilton Anxiety Scale (HAM-A), Hotel Dieu-16 a Sleep Hygiene Questionnaire(HD-16), and Clinical Clobal Impression-Change Scale (CGI-C)</title>
          <description>The Quality of Life in Essential Tremor Questionnaire (QUEST), Hamilton Anxiety scale (HAM-A) and Hotel Dieu-16 (HD-16) were scored as per published guidelines [7], [8] and [9]. The QUEST rates patient perception as influenced by tremor across 5 domains. A QUEST score will be between 0 and 120 with 0 = no essential tremor and 120 = severe essential tremor. The HAM-A rates the severity of anxiety symptomatology across 14 parameters. Scores of 14-17 = mild anxiety, 18-24 = moderate anxiety, and 25-30 = severe anxiety; The HD-16 rates insomnia-related quality of life across five domains. An HD-16 score of 73.1 - 248.5 = severe insomnia, 61-73.1 = mild insomnia, and 0 - 61 = good sleeper. For the scales, HAM-A, QUEST and HD-16, higher scores represent increased symptom severity or diminished quality of life. CGI-C was scored as follows: 1 = very much improved, 2=much improved, 3=mildly improved, 4=no change, 5=mildly worse, 6= much worse, and 7= very much worse.</description>
          <population>Change in secondary measures of efficacy compared with baseline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QUEST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="20.3"/>
                    <measurement group_id="O2" value="-9.7" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAM-A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="5.2"/>
                    <measurement group_id="O2" value="4.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HD-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="146.8"/>
                    <measurement group_id="O2" value="-38.6" spread="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGI-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.3"/>
                    <measurement group_id="O2" value="3.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome on study completers was assessed via ANOVA models using a 2 Ã— 2 Latin-square crossover design including sequence, period, and treatment effects. A significant carryover effect was excluded. Analyses were performed using Stata IC version 10.0 for Windows.&#xD;
Unfortunately the small sample size of our study limits the possibility of a meaningful post-hoc analysis targeted to these variables.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>ANOVA</method>
            <other_analysis_desc>The Quest rates patient perception of health status as influenced by tremor across 5 domains, physical, psychosocial, communication, hobbies/leisure, and work/finance. HAM-A rates severity of anxiety symptomatology across 14 parameters. Scores of 14-17 correspond to mild anxiety, scores of 18-24 is moderate anxiety and 25-30 severe anxiety. HD-16 rates insomnia-related QoL across 5 domains: physical symptoms, energy &amp; motivation, concentration, interpersonal relations and psychological symptoms. These scales were scored per published guidelines.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks of study duration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin</title>
          <description>pregabalin: 75 mg bid to 300 mg bid based on per subject tolerability</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo capsules: up to 4 capsules bid as tolerated</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>instability</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a investigator initiated trial that was completed in 2008 under 42 CFR 11.22 (b) and does not meet criteria. The study was a pilot and did not lead to registration nor to indication so this level of reporting is not be warranted.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Joseph Jankovic</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-6556</phone>
      <email>josephj@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

